Galectin-4 Is Involved in the Structural Changes of Glycosphingolipid Glycans in Poorly Differentiated Gastric Cancer Cells with High Metastatic Potential

Gastric cancer with peritoneal dissemination is difficult to treat surgically, and frequently recurs and metastasizes. Currently, there is no effective treatment for this disease, and there is an urgent need to elucidate the molecular mechanisms underlying peritoneal dissemination and metastasis. Our previous study demonstrated that galectin-4 participates in the peritoneal dissemination of poorly differentiated gastric cancer cells. In this study, the glycan profiles of cell surface proteins and glycosphingolipids (GSLs) of the original (wild), galectin-4 knockout (KO), and rescue cells were investigated to understand the precise mechanisms involved in the galectin-4-mediated regulation of associated molecules, especially with respect to glycosylation. Glycan analysis of the NUGC4 wild type and galectin-4 KO clones with and without peritoneal metastasis revealed a marked structural change in the glycans of neutral GSLs, but not in N-glycan. Furthermore, mass spectrometry (MS) combined with glycosidase digestion revealed that this structural change was due to the presence of the lacto-type (β1-3Galactosyl) glycan of GSL, in addition to the neolacto-type (β1-4Galactosyl) glycan of GSL. Our results demonstrate that galectin-4 is an important regulator of glycosylation in cancer cells and galectin-4 expression affects the glycan profile of GSLs in malignant cancer cells with a high potential for peritoneal dissemination.

[1]  N. Inaki,et al.  Suppression of galectin-4 attenuates peritoneal metastasis of poorly differentiated gastric cancer cells , 2023, Gastric Cancer.

[2]  S. Teneberg,et al.  Characterization of novel nonacid glycosphingolipids as biomarkers of human gastric adenocarcinoma , 2022, The Journal of biological chemistry.

[3]  S. Liang,et al.  Galectins in Cancer and the Microenvironment: Functional Roles, Therapeutic Developments, and Perspectives , 2021, Biomedicines.

[4]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[5]  Zhen Wang,et al.  Issues on peritoneal metastasis of gastric cancer: an update , 2019, World Journal of Surgical Oncology.

[6]  K. Mimori,et al.  Molecular mechanism of peritoneal dissemination in gastric cancer , 2018, Journal of Cancer Metastasis and Treatment.

[7]  H. Baba,et al.  Update on targeted therapy and immune therapy for gastric cancer, 2018 , 2018 .

[8]  Ruud P. M. Dings,et al.  Galectins as Molecular Targets for Therapeutic Intervention , 2018, International journal of molecular sciences.

[9]  Yongyi Zeng,et al.  Overexpression of galectin-4 promotes cell growth of hepatocellular carcinoma cells in vitro and in vivo. , 2017, International journal of clinical and experimental pathology.

[10]  Chien-Jen Chen,et al.  Promoter hypermethylation of LGALS4 correlates with poor prognosis in patients with urothelial carcinoma , 2017, Oncotarget.

[11]  Zhanqi Cao,et al.  The role of galectin-4 in physiology and diseases , 2016, Protein & Cell.

[12]  S. Pinho,et al.  Glycosylation in cancer: mechanisms and clinical implications , 2015, Nature Reviews Cancer.

[13]  J. Dennis,et al.  The galectin lattice at a glance , 2015, Journal of Cell Science.

[14]  Xiaolong Liu,et al.  Galectin-4 serves as a prognostic biomarker for the early recurrence / metastasis of hepatocellular carcinoma , 2014, Cancer science.

[15]  E. Giovannetti,et al.  Galectin-4 expression is associated with reduced lymph node metastasis and modulation of Wnt/β-catenin signalling in pancreatic adenocarcinoma , 2014, Oncotarget.

[16]  Robert G. Parton,et al.  Galectin-3 drives glycosphingolipid-dependent biogenesis of clathrin-independent carriers , 2014, Nature Cell Biology.

[17]  Kenji Suzuki,et al.  Galectin-4, a Novel Predictor for Lymph Node Metastasis in Lung Adenocarcinoma , 2013, PloS one.

[18]  Y. Igarashi,et al.  Qualitative and Quantitative Cellular Glycomics of Glycosphingolipids Based on Rhodococcal Endoglycosylceramidase-assisted Glycan Cleavage, Glycoblotting-assisted Sample Preparation, and Matrix-assisted Laser Desorption Ionization Tandem Time-of-flight Mass Spectrometry Analysis* , 2011, The Journal of Biological Chemistry.

[19]  S. Nishimura,et al.  Insight into glycan diversity and evolutionary lineage based on comparative Avio-N-glycomics and sialic acid analysis of 88 egg whites of Galloanserae. , 2011, Biochemistry.

[20]  Haike Ghazarian,et al.  A glycobiology review: carbohydrates, lectins and implications in cancer therapeutics. , 2011, Acta histochemica.

[21]  A. Minami,et al.  Threshold in Stage-specific Embryonic Glycotypes Uncovered by a Full Portrait of Dynamic N-Glycan Expression during Cell Differentiation* , 2009, Molecular & Cellular Proteomics.

[22]  G. Rabinovich,et al.  Galectins: structure, function and therapeutic potential , 2008, Expert Reviews in Molecular Medicine.

[23]  M. Nakano,et al.  Comprehensive approach to structural and functional glycomics based on chemoselective glycoblotting and sequential tag conversion. , 2008, Analytical chemistry.

[24]  R. Kannagi,et al.  Rapid demonstration of diversity of sulfatide molecular species from biological materials by MALDI-TOF MS. , 2006, Glycobiology.

[25]  J. Marth,et al.  Dietary and Genetic Control of Glucose Transporter 2 Glycosylation Promotes Insulin Secretion in Suppressing Diabetes , 2005, Cell.

[26]  D. Harvey.  Structural determination of N‐linked glycans by matrix‐assisted laser desorption/ionization and electrospray ionization mass spectrometry , 2005, Proteomics.

[27]  K. Yamashita,et al.  Galectin-4 Binds to Sulfated Glycosphingolipids and Carcinoembryonic Antigen in Patches on the Cell Surface of Human Colon Adenocarcinoma Cells* , 2005, Journal of Biological Chemistry.

[28]  M. Huflejt,et al.  Galectin-4 in normal tissues and cancer , 2003, Glycoconjugate Journal.

[29]  K. Yamashita,et al.  High-affinity binding of recombinant human galectin-4 to SO3–→3Galβ1→3GalNAc pyranoside , 2002 .

[30]  M. Green,et al.  High-energy collision-induced fragmentation of complex oligosaccharides ionized by matrix-assisted laser desorption/ionization mass spectrometry. , 1997, Journal of mass spectrometry : JMS.

[31]  X. Matías-Guiu,et al.  ABO (H) blood group antigen expression in gastric mucosa. , 1988, Pathology, research and practice.

[32]  J. Sakamoto,et al.  Analysis of the specificity of five murine anti-blood group A monoclonal antibodies, including one that identifies type 3 and type 4 A determinants. , 1985, Biochemistry.

[33]  Naoyuki Taniguchi,et al.  Glycans and cancer: role of N-glycans in cancer biomarker, progression and metastasis, and therapeutics. , 2015, Advances in cancer research.

[34]  Hiroaki Nakagawa,et al.  High-throughput protein glycomics: combined use of chemoselective glycoblotting and MALDI-TOF/TOF mass spectrometry. , 2004, Angewandte Chemie.

[35]  K. Yamashita,et al.  High-affinity binding of recombinant human galectin-4 to SO(3)(-)-->3Galbeta1-->3GalNAc pyranoside. , 2002, Glycobiology.